Sign up to save your podcasts
Or
Share 🌍 Obesity, Orals, Outcomes: Rewriting the GLP-1 Script
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
🌍 Obesity, Orals, Outcomes: Rewriting the GLP-1 Script
đź’Š Orforglipron: A new era in obesity treatment?
In the ATTAIN-1 trial, this oral, nonpeptide GLP-1 receptor agonist delivered up to 11.2% weight loss over 72 weeks—with significant drops in waist circumference, triglycerides, and blood pressure 📉🌡️
🔥 Nearly 1 in 5 patients lost ≥20% body weight
đź’ˇ A promising alternative to injectable therapies
Accessible. Effective. Oral.
👉 A game-changer for global obesity care?
#Obesity #GLP1 #Orforglipron #WeightLoss #CardiometabolicHealth #NEJM #Innovation #ClinicalTrials #Endocrinology #PublicHealth #Pharmacotherapy
View all episodes
By Dr RR Baliga, MD, MBA
5
66 ratings
đź’Š Orforglipron: A new era in obesity treatment?
In the ATTAIN-1 trial, this oral, nonpeptide GLP-1 receptor agonist delivered up to 11.2% weight loss over 72 weeks—with significant drops in waist circumference, triglycerides, and blood pressure 📉🌡️
🔥 Nearly 1 in 5 patients lost ≥20% body weight
đź’ˇ A promising alternative to injectable therapies
Accessible. Effective. Oral.
👉 A game-changer for global obesity care?
#Obesity #GLP1 #Orforglipron #WeightLoss #CardiometabolicHealth #NEJM #Innovation #ClinicalTrials #Endocrinology #PublicHealth #Pharmacotherapy
More shows like Dr RR Baliga's "Got Knowledge Doc" Podkast
View all
This Week in Cardiology
893 Listeners
The Curbsiders Internal Medicine Podcast
3,374 Listeners
The Mel Robbins Podcast
21,500 Listeners